Paris I - Search Results

1

Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitors.

Garufi G, Palazzo A, Paris I, Orlandi A, Cassano A, Tortora G, Scambia G, Bria E, Carbognin L. Garufi G, et al. Among authors: paris i. Expert Opin Pharmacother. 2020 Apr;21(6):687-699. doi: 10.1080/14656566.2020.1724957. Epub 2020 Feb 13. Expert Opin Pharmacother. 2020. PMID: 32052646 Review.

2

Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: updated results and long-term survival.

Ferrandina G, Paris I, Ludovisi M, D'Agostino G, Testa A, Lorusso D, Zanghi M, Pisconti S, Pezzella G, Adamo V, Breda E, Scambia G. Ferrandina G, et al. Among authors: paris i. Gynecol Oncol. 2005 Aug;98(2):267-73. doi: 10.1016/j.ygyno.2005.04.018. Gynecol Oncol. 2005. PMID: 15975643 Clinical Trial.

3

Secondary cytoreduction plus oxaliplatin-based HIPEC in platinum-sensitive recurrent ovarian cancer patients: a pilot study.

Fagotti A, Paris I, Grimolizzi F, Fanfani F, Vizzielli G, Naldini A, Scambia G. Fagotti A, et al. Among authors: paris i. Gynecol Oncol. 2009 Jun;113(3):335-40. doi: 10.1016/j.ygyno.2009.03.004. Epub 2009 Apr 5. Gynecol Oncol. 2009. PMID: 19345401 Clinical Trial.

4

Neoadjuvant Chemotherapy Followed by Maintenance Therapy With or Without Bevacizumab in Unresectable High-Grade Serous Ovarian Cancer: A Case-Control Study.

Petrillo M, Paris I, Vizzielli G, Amadio G, Cosentino F, Salutari V, Scambia G, Fagotti A. Petrillo M, et al. Among authors: paris i. Ann Surg Oncol. 2015 Dec;22 Suppl 3:S952-8. doi: 10.1245/s10434-015-4651-8. Epub 2015 Jun 3. Ann Surg Oncol. 2015. PMID: 26036187

5

Impact of bevacizumab containing first line chemotherapy on recurrent disease in epithelial ovarian cancer: A case-control study.

Petrillo M, Amadio G, Salutari V, Paris I, Di Stefano MG, Ferandina G, Scambia G, Fagotti A. Petrillo M, et al. Among authors: paris i. Gynecol Oncol. 2016 Aug;142(2):231-6. doi: 10.1016/j.ygyno.2016.05.017. Epub 2016 May 26. Gynecol Oncol. 2016. PMID: 27215633

6

Characterization of a new BRCA1 rearrangement in an Italian woman with hereditary breast and ovarian cancer syndrome.

Concolino P, Rizza R, Hackmann K, Paris I, Minucci A, De Paolis E, Scambia G, Zuppi C, Schrock E, Capoluongo E. Concolino P, et al. Among authors: paris i. Breast Cancer Res Treat. 2017 Jul;164(2):497-503. doi: 10.1007/s10549-017-4275-8. Epub 2017 May 9. Breast Cancer Res Treat. 2017. PMID: 28488140

7

BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.

Petrillo M, Marchetti C, De Leo R, Musella A, Capoluongo E, Paris I, Benedetti Panici P, Scambia G, Fagotti A. Petrillo M, et al. Among authors: paris i. Am J Obstet Gynecol. 2017 Sep;217(3):334.e1-334.e9. doi: 10.1016/j.ajog.2017.05.036. Epub 2017 May 23. Am J Obstet Gynecol. 2017. PMID: 28549976

8

Real-World Management of Trabectedin/Pegylated Liposomal Doxorubicin in Platinum-Sensitive Recurrent Ovarian Cancer Patients: A National Survey.

Ferrandina G, Amadio G, Paris I, Distefano M, Palluzzi E, de Vincenzo R, Ricci C, Scambia G. Ferrandina G, et al. Among authors: paris i. Int J Gynecol Cancer. 2017 Jul;27(6):1141-1148. doi: 10.1097/IGC.0000000000001058. Int J Gynecol Cancer. 2017. PMID: 28574933

9

Efficacy and safety of T-DM1 in the 'common-practice' of HER2+ advanced breast cancer setting: a multicenter study.

Fabi A, De Laurentiis M, Caruso M, Valle E, Moscetti L, Santini D, Cannita K, Carbognin L, Ciccarese M, Rossello R, Arpino G, Leonardi V, Montemurro F, La Verde N, Generali D, Zambelli A, Scandurra G, Russillo M, Paris I, D'Ottavio AM, Filippelli G, Giampaglia M, Stani S, Fabbri A, Alesini D, Cianniello D, Giannarelli D, Cognetti F. Fabi A, et al. Among authors: paris i. Oncotarget. 2017 Mar 18;8(38):64481-64489. doi: 10.18632/oncotarget.16373. eCollection 2017 Sep 8. Oncotarget. 2017. PMID: 28969087 Free PMC article.

10

Preliminary molecular evidence associating a novel BRCA1 synonymous variant with hereditary ovarian cancer syndrome.

Minucci A, Concolino P, De Bonis M, Costella A, Paris I, Scambia G, Capoluongo E. Minucci A, et al. Among authors: paris i. Hum Genome Var. 2018 Apr 20;5:2. doi: 10.1038/s41439-018-0003-0. eCollection 2018. Hum Genome Var. 2018. PMID: 29760936 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

166 results

Search Page

Filters